Market research
DBV.PA DBV Technologies S.A
PA EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 599M
- P/E ratio
- Not available
- Analyst target
- 3.6367
- Dividend yield
- Not available
- Beta
- -0.24
Profile
Instrument facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0010417345
- Market cap
- 599M
- P/E ratio
- Not available
- Analyst target
- 3.6367
- Dividend yield
- Not available
- Beta
- -0.24
About
About DBV Technologies S.A
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Research context
DBV Technologies S.A appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the DBV.PA discussion.
5 years, 6 months ago
DBV Technologies S.A is currently in a long term uptrend where the price is trading 21.8% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
DBV Technologies S.A's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-42M since the same quarter in the previous year.
Finally, its free cash flow fell by 60.8% to $-35M since the same quarter in the previous year.
Based on the above factors, DBV Technologies S.A gets an overall score of 2/5.